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Original Article 
Impact of bodyweight / body mass index on the effectiveness of 
emergency contraception with levonorgestrel: a pooled-analysis of 
three randomized controlled trials 
K. Gemzell-Danielsson, L. Kardos, H. von Hertzen 
doi: 10.1185/03007995.2015.1094455 
Abstract 
Objective: A pooled analysis of 2 randomized controlled trials (RCTs) 
suggested that increased bodyweight and body mass index (BMI) may be 
associated with a greater probability of pregnancy. To address this issue 
we investigated whether higher bodyweight and/or BMI negatively 
impacted the risk of pregnancy in women receiving LNG-EC 
(levonorgestrel-emergency contraception) after unprotected sexual 
intercourse in a pooled analysis of three large multinational RCTs 
conducted by the World health Organization (WHO). 
Methods: A pooled-analysis of 3 double-blind, multinational RCTs 
conducted by the WHO to investigate the efficacy of LNG-EC in the 
general population. All analyses were done on the per-protocol set which included 5812 women who received 
LNG-EC within 72 hours following unprotected sexual intercourse. The analysis was based on logistic 
regression, with pregnancy as the outcome. BMI and weight were represented in the same model. 
Results: A total of 56 pregnancies were available for analysis in the PPS. Increasing bodyweight and BMI 
were not correlated with an increased risk of pregnancy in the studied population. A limitation of this study is 
that despite the large study population in the pooled-analysis there were relatively small numbers of women in 
the high-BMI and high-bodyweight subgroups. 
Conclusion: LNG-EC is effective for preventing pregnancy after unprotected intercourse or contraceptive 
failure and no evidence was found to support the hypothesis of a loss of EC efficacy in subjects with high BMI 
or bodyweight. Therefore, access to LNG-EC should not be limited only to women of lower bodyweight or BMI. 
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Abstract 
Objective: A pooled analysis of 2 randomized controlled trials (RCTs) suggested that increased 
bodyweight and body mass index (BMI) may be associated with a greater probability of 
pregnancy. To address this issue we investigated whether higher bodyweight and/or BMI 
negatively impacted the risk of pregnancy in women receiving LNG-EC (levonorgestrel-
emergency contraception) after unprotected sexual intercourse in a pooled analysis of three large 
multinational RCTs conducted by the World health Organization (WHO).  
Methods: A pooled-analysis of 3 double-blind, multinational RCTs conducted by the WHO to 
investigate the efficacy of LNG-EC in the general population. All analyses were done on the 
per-protocol set which included 5812 women who received LNG-EC within 72 hours following 
unprotected sexual intercourse. The analysis was based on logistic regression, with pregnancy as 
the outcome. BMI and weight were represented in the same model. 
Results: A total of 56 pregnancies were available for analysis in the PPS. Increasing 
bodyweight and BMI were not correlated with an increased risk of pregnancy in the studied 
population. A limitation of this study is that despite the large study population in the pooled-
analysis there were relatively small numbers of women in the high-BMI and high-bodyweight 
subgroups.  
Conclusion: LNG-EC is effective for preventing pregnancy after unprotected intercourse or 
contraceptive failure and no evidence was found to support the hypothesis of a loss of EC 
efficacy in subjects with high BMI or bodyweight. Therefore, access to LNG-EC should not be 
limited only to women of lower bodyweight or BMI.  
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Introduction 
Emergency contraception (EC), also known as post-coital contraception, refers to contraceptive 
methods that can be used to prevent pregnancy after unprotected or inadequately protected 
sexual intercourse. To be effective, EC should be used within a limited time frame, which 
depends on the method, but ranges from 72 to 120 hours after sexual intercourse
1
.  
During the last 15 years, following large multinational double-blind, randomized controlled 
trials (RCTs) conducted by the WHO, EC pills containing levonorgestrel (LNG-EC) have 
emerged as the most widely available and recommended method for oral EC
2-5
. Several studies 
have been conducted to establish the efficacy and safety of a standard regimen of LNG 1.5 mg 
(administered in two doses of 0.75 mg taken 12 hours apart or as a single-dose)
3-5
. To be 
effective, LNG-EC should be used as soon as possible after the unprotected sexual intercourse 
and within 72 hours. LNG-EC can inhibit or delay ovulation through an effect on follicular 
development
6
.   However, when luteinizing hormone (LH) levels start to rise LNG cannot 
prevent ovulation and it has no effect post-ovulation
7
. LNG-EC cannot prevent implantation and 
has no negative impact on a pregnancy should it occur
8
.  
Recently, the progesterone receptor modulator ulipristal acetate (UPA) has emerged as a novel 
oral method for EC which can be effective up to 120 hours after intercourse
9
. UPA-EC is still 
not as widely available as LNG. The European Medicines Agency’s (EMA) Committee for 
Medicinal Products for Human Use (CHMP) has recommended a change in classification status 
from prescription to non-prescription for the UPA containing emergency contraceptive, however 
it has not been approved by all EU countries as yet
10
. In a meta-analysis including data from two 
RCT single-blind trials UPA appeared more effective in preventing pregnancy (2 trials; RR 
0.63) than LNG, but the difference did not achieve statistical significance (P = 0.09)
9,11
. An 
influence of bodyweight and body mass index (BMI) on efficacy for both compounds was 
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reported by Glasier and co-authors; however, it was more pronounced for LNG-EC
12
. Not 
surprisingly, it was found that the cycle day that the unprotected intercourse took place, as well 
as further acts of unprotected intercourse after EC were both related to an increased risk of 
pregnancy. Other variables such as age, time from unprotected intercourse to EC and history of 
previous pregnancy were not shown to contribute to the risk of pregnancy.    
Overweight and obesity are increasing health problems worldwide. In many parts of the world, 
the problem is most pronounced among women of reproductive age. Based on the above-
mentioned finding of an influence of bodyweight on the efficacy of EC pills, access to LNG-EC 
has been questioned  in some countries. As a consequence, overweight women may have fewer 
options for EC and this is despite the fact that neither of the studies analyzed by Glasier and 
colleagues, or any other studies evaluating EC effectiveness, has been specifically designed to 
explore the effect of bodyweight on the effectiveness of EC
12
. Since timely access to EC is 
recognized as an important component of a woman's reproductive health status and choices, it is 
crucial to further explore a possible effect of bodyweight and/or BMI on LNG-EC efficacy to 
ascertain whether there is a direct correlation to EC failure. To date only retrospective data 
analyses of clinical studies performed in the general population have been published. The more 
substantive the information base that we analyse the better our position will be to offer sound 
advice regarding EC to women with higher bodyweights / BMIs.  
Thus, the aim of the present study was to examine whether the effectiveness LNG-EC was 
influenced by bodyweight and/or BMI based upon individual data derived from previously 
published, large, randomized, controlled trials in the general population conducted by the World 
Health Organization (WHO) Task Force on Postovulatory Methods for Fertility Regulation.  
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Methods 
Data 
Data were extracted from the levonorgestrel arms of three randomized, double-blind, clinical 
trials of EC conducted by the World Health Organization (WHO) Task Force on Postovulatory 
Methods for Fertility Regulation using a similar design
3-5
.  In brief these trials were: 
 A comparison with Yuzpe regimen (2 doses of ethinylestradiol 100 µg plus 
levonorgestrel 0.5 mg or d,l norgestrel 1.0 mg administered 12 hours apart) in which 
1001 women (mean age 27.3 years) were allocated to receive LNG-EC administered as 
two doses of 0.75 mg taken 12 hours apart
3
. 
 A comparison with mifepristone (10 mg single-dose) in which 1379 women were 
allocated to receive LNG-EC 1.5 mg as a single-dose and a further 1377 women two 
doses of LNG 0.75 mg taken 12 hours apart
4
. The mean age was 27 (range 14-52) years. 
 A comparison of single-dose LNG-EC 1.5 mg (n=1512) with LNG-EC administered as 
two doses of 0.75 mg taken 12 hours apart (n=1510)
5
. The mean age was 26 years. 
 
Statistical analysis and outcomes 
All descriptions and analyses were performed on the per-protocol set (PPS) which comprised 
women who took the EC within the recommended 72-hour time period and who had available 
follow-up data. Treatment delay values (hours between unprotected intercourse and 
administration of EC) less than zero or exceeding 72 hours, in accordance with the approved use 
of LNG-EC pills (Product Information), were excluded from the PPS. Women with missing 
values regarding pregnancy outcome after the unprotected intercourse (yes or no) were also 
excluded. Subject characteristics were described in terms of mean and standard deviation (SD) 
for continuous variables, and absolute and relative category frequencies for categorical 
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variables. Non-pregnant and pregnant subjects were visualized on scatter plots of bodyweight 
versus body height. For descriptive purposes, BMI was categorized with cut points at 18, 25, 30, 
and 35 kg/m
2
, and bodyweight with cut points at 55, 65, 75, and 85 kg. Empirical relative 
frequencies of pregnancy were expressed for all existing combinations of these categories, in 
percentage form with exact binomial 95% confidence intervals (CI). Subjects whose unprotected 
intercourse had occurred during the fertile window (beginning 5 days before and ending one day 
after expected ovulation) were assigned conception probability values following the Trussell 
model
13
. For intercourse days outside this range, but within days -28 to +14 (inclusive), the 
probability was set to zero, otherwise to missing. 
Analysis was based on logistic regression using the statistical software Stata (StataCorp), with 
pregnancy as the outcome. BMI and bodyweight were both represented in the same model as 
continuous variables. Quadratic and cubic variants, as well as interaction terms, were used to 
enable the model to follow curvatures of the outcome function. Other explanatory variables were 
included unless observed to have a neutral behavior, with quadratic or cubic terms if this 
improved model fit. Effects were expressed as odds ratios (OR) and 95% CIs. Model fit was 
assessed using the Hosmer–Lemeshow test and by visual comparison of observed and fitted 
probabilities across BMI and weight groups. P values less than 0.05 were considered to indicate 
statistical significance. 
Results 
The number of unique, single-subject records remaining after data cleaning was 6779, with 72 
pregnancies (Figure 1). A total of 916 records were eliminated; in the majority cases the patient 
had received EC after the allowed 72-hour time period, but before 120 hours which was 
permitted in some centres. Thus, 5863 subjects (59 pregnancies) were included in the PPS for 
the meta-analysis, with a pregnancy rate of 1%. 
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Subject characteristics are described in Table 1. On average, subjects were relatively young, 
with BMI in the healthy range, and treatment delay exceeding one day; almost two-thirds had 
been pregnant before. A special subgroup of women (N=60) who were exceptionally short for 
their weight was identified by plotting bodyweight against body height; the phenomenon 
occurred almost exclusively in 3 of 9 study groups in Nigeria (Africa). Of note, these subjects 
represented 1% of the sample, but 4 of 59 (6.8%) pregnancies. In this anthropological subset the 
relative frequency of pregnancy was 6.7% compared to 0.9% in the remainder of the total 
sample. The findings were also in sharp contrast to the full African data, where pregnancy risk 
was generally the lowest (0.5% including the contribution of these subjects) compared to other 
geographic regions. 
The observed unadjusted relationship between BMI, bodyweight and pregnancy is shown in 
Figure 2. There is an isolated hotspot at around BMI 32.5 kg/m
2
 and bodyweight between 55 
and 74 kg. Also, there is a marginal ramp coinciding with a single pregnancy in subjects who are 
at the high end of the BMI and bodyweight range. Both these peaks are fully explained by the 
subgroup found within the 3 above-mentioned Nigerian study sites (they disappear from the heat 
map if these subjects are excluded). The probability plane being highly and irregularly curved 
indicated that a logistic regression model would require higher order terms for a plausible fit. It 
is also evident that the effect of BMI is heterogeneous across levels of bodyweight, and vice 
versa, making it necessary to use interaction terms between the two. 
A logistic regression model with squared and cubed BMI and bodyweight terms and interactions 
was fitted and found to be consistent with the data. Other explanatory variables included 
continent, treatment delay, expected probability of pregnancy, and age. The fit was sufficient 
according to the Hosmer–Lemeshow test (p = 0.236), and a heat map of fitted probabilities 
indicated that both the isolated hot spot and the top-edge marginal ramp were retained. The 
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marginal effects of BMI, bodyweight, treatment delay, expected probability of pregnancy, and 
age were selectively significant in a location-dependent manner. 
Effects of BMI and bodyweight 
The estimated marginal effects associated with a unit increase in BMI from a defined reference 
level were mostly very close to neutral or had very wide CIs. One group of technically 
significant effects was located at reference BMI in the range 24 to 30 kg/m
2
, and bodyweight 
between 50 and 65 kg, with an odds ratio of up to 1.47 (95% CI: 1.13 to 1.92) and the effect 
exceeding a narrow range of equivalence (OR between 1/1.1 and 1.1). A single additional, very 
weakly significant effect (OR 2.18 [95% CI: 1.03 to 4.62]) appeared at BMI 44 kg/m
2
 and 
bodyweight 80 kg, consistent with the top-edge ramp.  
The estimated effects of bodyweight were similar to those of BMI in terms of size of departure 
from neutrality and patterns of uncertainty. Statistically significant effects were located in the 
BMI range 26 to 30 kg/m
2
, and bodyweight between and 65 and 70 kg. At higher bodyweights 
relative to BMI, the risk of pregnancy decreased (Table 2). This corresponds to the downward 
slope from the top of the isolated hot spot towards greater bodyweights with BMI remaining 
constant. Marginal effects were almost exclusively inside a wide range of equivalence (OR 
between 1/1.25 and 1.25) or exceeded it primarily towards the negative direction in the area 
defined by the BMI range 18 to 24 kg/m
2
, and weight range 45 to 60 kg. Table 2 illustrates how 
these effects manifest across the outcome space as a function of BMI and body weight, relative 
to a reference point of 22.5 kg/m2 and 60 kg, i.e., women with close to the average body 
characteristics in the current sample. 
Effects of other factors 
The odds of pregnancy were significantly lower in Africa than in the reference category of non-
African, non-Asian regions (OR = 0.26). There was no significant difference between Asia and 
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the non-African, non-Asian population. Across the observed age range, the probability of 
pregnancy initially increased, peaked at around 30 years, and then declined. The rate of the 
increase was significant in the range 15 to 25 years, and that of the decline, from 45 years and 
beyond. 
Up to 48 hours delay in providing EC was not observed to influence the chances of pregnancy. 
However, a progressively significant rise in the risk of pregnancy occurred when the delay in 
giving EC reached 54 hours, a point beyond which further delay meant a loss of EC efficacy. 
Across the observed range, greater expected conception probability (Trussell method) was 
generally associated with greater odds of pregnancy
13
. The rate of this increase was initially 
highest, gradually declined, and leveled out at about 20%. Higher levels of estimation 
uncertainty in the low expected probability range meant that the marginal effects did not reach 
significant levels except at 12% as the reference location. 
Discussion 
The pooled data from the 3 clinical trials in this meta-analysis including 5812 women with 56 
registered cases of pregnancy following the use of LNG-EC (with a treatment delay of not more 
than 72 hours) showed a high overall contraceptive effectiveness with a pregnancy risk between 
0.57% and 1.8%. The pregnancy rate in the whole population was 1%. High BMI or bodyweight 
were not substantiated as factors increasing the risk of pregnancy. All adjusted marginal effects 
of BMI that were technically significant are explained by the presence of a single 
anthropological subgroup of women who were exceptionally short for their weight; this group is 
atypical to such an extent that any generalization of these seemingly positive findings beyond 
the limits of the study sample would be prohibitively difficult. Increased bodyweight was not 
observed to be significantly associated with greater probabilities of pregnancy; its significant 
(pseudo)protective effects can be explained as artifacts, again as a result of the cluster of 
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pregnancies described above. The strength of support provided by this evidence for a hypothesis 
of loss of EC efficacy in high-BMI subjects (as proposed in a previous meta-analysis by Glasier 
et al., 2011) is zero to extremely limited
11
. 
There are no data indicating that obesity would reduce the contraceptive efficacy of combined 
hormonal contraceptives
14
.
 
The previous meta-analysis by Glasier and colleagues involving two 
studies by Creinin et al. and Glasier et al. reported a significant influence of bodyweight and 
BMI on the efficacy of EC pills, and this was slightly more pronounced for LNG-EC compared 
with UPA-EC
9,11,12
. Several possible factors could contribute to the different findings. These 
factors alone might not cause significant change in the overall picture, but could reinforce or 
weaken a tendency. Firstly, the treatment delay may be different in the two meta-analyses (120 
versus 72 hours). There are no details available on the fraction of women who received LNG-EC 
beyond the labelled 72 hours’ time frame in the meta-analysis by Glasier and colleagues to 
assess whether this affected the risk of pregnancy. Secondly, in one of the studies included in the 
efficacy evaluation of the pooled data the women themselves estimated their weight which was 
not objectively controlled
12. This methodology may be problematic as the ‘efficacy evaluable’ 
population criteria are not identical in the two studies. Thirdly, the use of the analyzed 
populations (evaluability according to treatment delay or other criteria) seems to be inconsistent 
within the key publications 
9,11
. Noticeably, the studies included in the present analysis 
contained data from patients who had only one act of unprotected intercourse before taking 
LNG-EC in contrast to the criteria in the studies included in the meta-analysis by Glasier and 
colleagues
11
.  
The findings regarding the effects of secondary explanatory factors are plausible and consistent 
with current knowledge, indicating the existence of an age range within which fecundity reaches 
a peak, the importance of timely post-coital intervention, and an association between calculated 
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baseline probability of pregnancy and observed frequency of conception. This is also consistent 
with the mechanisms of action of LNG-EC. 
The decision to include both BMI and bodyweight in the current model seemingly contrasts with 
usual practice of avoiding correlated covariates. The conceptual basis for including both relates 
to the fact that high bodyweight can be the result of accumulated body fat (i.e. overweight), but 
may also be explained by a generally big body with a healthy tissue composition. High BMI can 
also result from high body fat, but will also be found in tall people (or very muscular persons) 
with significantly less body fat than their BMI would suggest. Analyzing either variable 
separately will thus yield compound effects of body size and fat content. However, when 
analyzing the effect of bodyweight with BMI held constant, the observed effect will be much 
closer to that of body size (overall pharmacokinetic distribution space) alone; and when 
analyzing the effect of BMI with bodyweight held constant, the observed effect will better 
represent that of body adipose tissue content or changes in lipid-to-water ratio (important 
pharmacokinetic consequences for lipophilic substances). If there is a loss of efficacy resulting 
from either of these two mechanisms, the current model will be more sensitive to determine this 
association since both BMI and bodyweight are used as exploratory variables. These general 
considerations for variable inclusion are further corroborated, in the present case, by prominent 
effect heterogeneity phenomena between BMI and bodyweight. 
Limitations 
A limitation of the current analysis is that high-BMI and high-bodyweight ranges were relatively 
poorly populated in the analyzed dataset, as might be expected for a study which did not 
specifically recruit to ensure sufficient coverage close to those higher distribution extremes. 
Nevertheless, we believe that the present analysis delivers an important general message. Post 
hoc analyses of historic data to address safety or efficacy concerns are common, even when they 
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were not originally designed to specifically address these outcomes. Another limitation of this 
type of analysis is dependency on self-reporting of some data such as time interval after 
intercourse, cycle length, and the number of times intercourse took place before and after 
treatment. Because of the relatively small number of pregnancies (n=56), caution has to be 
shown when interpreting the results. For example, it is possible with our current data to fit a 
model that predicts significantly growing pregnancy odds with increasing BMI, and that model 
will pass a common goodness-of-fit test. However, the BMI effect in that model will be highly 
dubious, and is fully explained by three pregnancy observations, all in a single anthropological 
subgroup.  
Conclusion 
Based on the results of this analysis involving 5812 women, no evidence was found supporting 
the hypothesis of loss of EC efficacy in subjects with high BMI or bodyweight. Therefore, as 
has recently been concluded by the EMA, based on the data presented here, access to LNG-EC 
should not be limited to women of lower bodyweight or BMI (EMA Assessment Report 2014)
15
. 
Any increase in EC efficacy that is achieved is beneficial to the great number of women who 
have already had unprotected intercourse, offering them a second chance to prevent an 
unintended pregnancy. 
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Figure legends. 
Figure 1 Subject flow profile.  
The per-protocol (PP) population using the product within the 0-72 hour time frame was 5863 
(59 pregnant). PP population using the product within the 0-72 hour time frame and data 
about BMI status not missing: 5859 (59 pregnant). PP population using the product within the 
0-72 hour time frame and all pre-defined variables in the analysis reported: 5812 (56 
pregnant). 
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Figure 2. Empirical probability (%) heat map of pregnancy in subgroups defined by BMI and 
bodyweight. Figures in parentheses indicate numerators and denominators from which 
percentages were derived; those in square brackets indicate 95% confidence intervals for the 
percentage. 
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Table 1 Characteristics of subjects and crude pregnancy rates  
Characteristic N 
Mean (SD)        or 
n (%) 
Crude pregnancy risk (%) 
[95% CI]) 
Continuous variables 
   
Age 
586
2 
27.0 (6.5) N/A 
Bodyweight [kg] 
585
9 
59.5 (10.3) N/A 
Body height [cm] 
586
0 
162.6 (6.7) N/A 
Body Mass Index [kg/m
2
] 
585
9 
22.5 (3.9) N/A 
Treatment delay [h] 
586
3 
29.9 (18.7) N/A 
Expected probability of 
pregnancy [%] 
581
6 
9.1 (10.9) N/A 
Length of menstrual cycle [d] 
586
3 
28.8 (2.4) N/A 
Categorical variables       
Pregnant 
586
3 
  
no 
 
5804 (99.0%) N/A 
yes   59 (1.0%) N/A 
Body Mass Index [kg/m
2
] group 
585
9 
  
13.84 - 18.00 
 
406 (6.9%) 1.7 [0.7 to 3.5] 
18.03 - 25.00 
 
4158 (71.0%) 1.0 [0.7 to 1.4] 
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25.01 - 29.93 
 
1039 (17.7%) 0.6 [0.2 to 1.3] 
30.02 - 34.89 
 
202 (3.4%) 1.0 [0.1 to 3.5] 
35.00 - 51.20   54 (0.9%) 1.9 [0.0 to 9.9] 
Bodyweight [kg] group 
585
9   
30 - 54 
 
2008 (34.3%) 1.3 [0.9 to 2.0] 
55 - 64 
 
2168 (37.0%) 1.1 [0.7 to 1.6] 
65 - 74 
 
1180 (20.1%) 0.6 [0.2 to 1.2] 
75 - 84 
 
399 (6.8%) 0.5 [0.1 to 1.8] 
85 - 130   104 (1.8%) 0.0 [0.0 to 3.5] 
Continent 
586
3   
Am/Aus/Eur 
 
1255 (21.4%) 1.0 [0.5 to 1.7] 
Africa 
 
2683 (45.8%) 0.5 [0.3 to 0.9] 
Asia   1925 (32.8%) 1.7 [1.2 to 2.4] 
Treatment group 
586
3   
Single 1.50mg 
 
2461 (42.0%) 0.9 [0.6 to 1.4] 
Double 0.75mg   3402 (58.0%) 1.1 [0.8 to 1.5] 
Further intercourse* # 
585
6 
  
no 
 
3806 (65.0%) 0.9 [0.6 to 1.3] 
yes   2050 (35.0%) 1.2 [0.8 to 1.7] 
Number of further acts of 
intercourse* # 
204
9 
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1 
 
699 (34.1%) 1.3 [0.6 to 2.4] 
2 
 
627 (30.6%) 1.1 [0.5 to 2.3] 
>2   723 (35.3%) 1.0 [0.4 to 2.0] 
Previous pregnancies 
586
3   
none 
 
2110 (36.0%) 0.7 [0.4 to 1.2] 
1 or more   3753 (64.0%) 1.2 [0.9 to 1.6] 
 
Confidence intervals (CI) for rate point estimates of 0.0% are one-sided 97.5% intervals. 
N = number of non-missing observations, * Refers to the current menstrual cycle,             
# Protected intercourse. Women were advised not to have unprotected sex, and were 
given condoms. Participants were asked in the single studies to keep a diary of side-
effects in the week after the treatment, and to record when a condom was used. 
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Table 2 Odds ratios [95% confidence intervals] for pregnancy at selected levels of BMI and 
bodyweight relative to the odds at the reference point of 22.5 kg/m
2
 and 60 kg. N/A indicates 
locations of insufficient sample coverage for effect estimation 
BMI\BW 40 45 50 55 60 65 70 75 80 
18 
2.15 
[0.41 - 
11.3] 
1.51 
[0.63 - 
3.59] 
1.83 
[0.90 - 
3.74] 
2.62 
[0.85 - 
8.10] 
2.98 
[0.39 - 
22.6] 
N/A N/A N/A N/A 
20 N/A 
1.80 
[0.54 - 
5.99] 
1.32 
[0.73 - 
2.42] 
1.26 
[0.84 - 
1.89] 
1.19 
[0.55 - 
2.58] 
0.86 
[0.11 - 
6.67] 
N/A N/A N/A 
22.5 N/A N/A 
2.16 
[0.81 - 
5.75] 
1.42 
[0.88 - 
2.28] 
reference 
point 
0.67 
[0.35 - 
1.29] 
0.38 
[0.046 - 3.16] 
N/A N/A 
25 N/A N/A 
5.17 
[1.03 - 
25.9] 
3.10 
[1.17 - 
8.17] 
1.74 
[1.00 - 
3.05] 
0.94 
[0.55 - 
1.60] 
0.50 
[0.19 - 1.31] 
N/A N/A 
30 N/A N/A N/A 
13.7 
[2.14 - 
87.2] 
10.9 
[2.06 - 
57.4] 
4.53 
[0.91 - 
22.6] 
1.32 
[0.23 - 7.41] 
0.35 
[0.030 - 4.09] 
N/A 
40 N/A N/A N/A N/A N/A N/A 
12.5 
[0.12 - 1339] 
1.02 
[0.0022 - 
475] 
0.011 
[1.0×10-7 - 
1072] 
50 N/A N/A N/A N/A N/A N/A N/A N/A 
483 
[1.69 - 138500] 
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